Nephrol Dial Transplant (2001) 16: 787-792
© 2001 European Renal Association-European Dialysis and Transplant Association
Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients
My
liwiecDepartment of Nephrology and Internal Medicine, Medical Academy, Bialystok, Poland
Background. The level of soluble thrombomodulin (sTM), a traditional marker of endothelial injury, is also dependent on renal excretory function. We studied serum sTM in chronic haemodialysis (HD) patients to determine which factors are predictive of its levels in this population.
Methods and results. sTM levels of 10.7 (5.72–30.7) ng/ml in 100 HD patients were higher than in 30 controls (P<0.0001). In a bivariate regression analysis, immunoreactive sTM was positively associated with the presence of hepatitis B virus surface antigen and/or anti-hepatitis C virus antibodies measured by third generation ELISAs (P<0.0001), and was related to certain markers of liver injury and biosynthetic dysfunction. sTM was also directly associated with time on dialysis (P=0.001), or use of unfractionated heparin (UFH) (vs enoxaparin) (P=0.0007), erythropoietin (P=0.008), ACE-inhibitors (P=0.034), acetate-buffered dialysate (vs bicarbonate) (P=0.040), pre-dialysis systolic (P=0.012), and diastolic blood pressure (P=0.043). It was negatively associated with lipoprotein(a) (P=0.029). sTM was not related to age, sex, smoking, cause of renal failure, prevalence of cardiovascular disease, amount of HD delivered, preserved residual renal function, ferritin, C-reactive protein, and other vasoactive medications used. In a multivariable analysis, a positive hepatitis marker (P=0.0002), the use of UFH (P=0.030) and erythropoietin (P=0.019), and raised pre-dialysis blood pressure (P=0.024) were positive independent predictors of high sTM level.
Conclusion. These data indicate that, in addition to endothelial activation, elevated sTM levels in HD patients may be related to viral infection and/or liver dysfunction, and influenced by modifiable factors such as increased blood pressure, and the type of heparin and erythropoietin treatment used.
Keywords: arterial blood pressure; erythropoietin; haemodialysis; heparin; soluble thrombomodulin; viral hepatitis
Correspondence and offprint requests to: Dr Jacek Borawski, Department of Nephrology and Internal Medicine, Medical Academy, 14 Zurawia Street, PL-15-540 Bialystok, Poland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Stasko and P. Kubisz Increased Soluble Thrombomodulin in Hemodialysis Patients with Long-term Erythropoietin Treatment: What Does it Reflect? Clinical and Applied Thrombosis/Hemostasis, October 1, 2003; 9(4): 349 - 352. [PDF]
|
|
|
|
|
|
J. Borawski, B. Naumnik, and M. Mysliwiec Tissue Factor and Thrombomodulin in Hemodialysis Patients: Associations with Endothelial Injury, Liver Disease, and Erythropoietin Therapy Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 359 - 367. [Abstract] [PDF]
|
|
|
|
|
|
B. Naumnik, J. Borawski, K. Pawlak, and M. Mysliwiec Effect of Hemodialysis on Plasma Levels of Vascular Endothelial Markers Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 245 - 250. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Borawski and M. Mysliwiec Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients Nephrol. Dial. Transplant., April 1, 2002; 17(4): 637 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Borawski and M. Mysiwiec Effects of Recombinant Erythropoietin Therapy on Circulating Endothelial Markers in Hemodialysis Patients Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 77 - 84. [Abstract] [PDF]
|
|
|
|
|
|
J. Borawski, B. Naumnik, and M. Mys'liwiec Increased Soluble Thrombomodulin Does Not Always Indicate Endothelial Injury Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 87 - 89. [PDF]
|
|